.

Dynavax Technologies reported $221.03M in Loan Capital for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Amgen AMGN:US $ 35705M 305M
AstraZeneca AZN:LN 2229663.86M 36335.94M
Astrazeneca AZN:US 27.15B 1.66B
Biogen BIIB:US $ 6277.4M 1.7M
Biomarin Pharmaceutical BMRN:US $ 1081.05M 0.99M
Bristol Myers Squibb BMY:US $ 37107M 343M
Chimerix CMRX:US $ 0 0
Dynavax Technologies DVAX:US $ 221.03M 0.27M
Glaxosmithkline GSK:US $ 18784M 10442M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Novartis NOVN:VX SF 23784M 589M
Regeneron Pharmaceuticals REGN:US $ 2700.7M 0.3M
Sarepta Therapeutics SRPT:US $ 1100.87M 2.03M
Vertex Pharmaceuticals VRTX:US $ 482.3M 13.2M